All Trials

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after ≥4 cycles first-line platinum and 6 cycles second-line carboplatin doublet (ECOG 0–1) randomized to maintenance sacituzumab tirumotecan (TROP2-directed antibody–drug conjugate delivering a belotecan-derived topoisomerase I inhibitor) with optional bevacizumab versus standard-of-care maintenance with optional bevacizumab. Excludes platinum-resistant/refractory and non-epithelial/borderline histologies and patients with significant ocular disease, active IBD, uncontrolled CV/cerebrovascular disease, prior severe ILD/pneumonitis, or active CNS metastases.

ClinicalTrials.gov ID: NCT06824467

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of INCB123667, an oral selective CDK2 inhibitor targeting Cyclin E–driven cell-cycle progression, in adults with high-grade serous ovarian/fallopian tube/primary peritoneal cancer that is platinum-resistant and CCNE1/Cyclin E1–overexpressing. Eligible patients have had 1–4 prior regimens with prior bevacizumab (and mirvetuximab if FRα-positive) unless contraindicated; exclusions include non–HGS histology, primary platinum-refractory disease, and active CNS metastases.

ClinicalTrials.gov ID: NCT07023627

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer after prior systemic therapy are randomized to avutometinib (a dual RAF/MEK “clamp”) plus defactinib (FAK/Pyk2 inhibitor) versus investigator’s choice of pegylated liposomal doxorubicin, weekly paclitaxel, letrozole, or anastrozole. Requires measurable disease, ECOG 0–1, and known KRAS status; crossover to the combo is allowed at progression.

ClinicalTrials.gov ID: NCT06072781

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Upfront therapy for adult women with measurable low-grade serous ovarian or primary peritoneal carcinoma who are not candidates for primary cytoreduction or have residual disease after suboptimal debulking. Patients receive avutometinib (dual RAF/MEK clamp) plus defactinib (FAK inhibitor) on a 3-weeks-on/1-week-off schedule with continuous letrozole (and ovarian suppression if pre/perimenopausal).

ClinicalTrials.gov ID: NCT06394804

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (1–3 prior lines; prior bevacizumab and PARP inhibitor as indicated) are randomized to the CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd; cleavable linker to DXd topoisomerase I payload) given IV q3w versus investigator’s choice of weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan. Requires measurable disease, ECOG 0–1, available tumor tissue; excludes prior CDH6/DXd ADCs and patients with active ILD/pneumonitis or significant uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT06161025

Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults and adolescents (≥12) with unresectable stage IIIb–IV cutaneous melanoma progressing after anti–PD-1 and anti–CTLA-4 (with measurable, injectable lesions) are randomized to intratumoral vusolimogene oderparepvec (RP1), an engineered HSV‑1 oncolytic immunotherapy expressing GM‑CSF and GALV‑GP R-, plus nivolumab versus physician’s choice (Opdualag, anti–PD‑1 monotherapy, or single‑agent chemotherapy). Excludes mucosal/uveal melanoma, active CNS mets, >2 prior systemic lines, high LDH, significant autoimmune/infectious risks, or prior oncolytic/intratumoral therapy.

ClinicalTrials.gov ID: NCT06264180

A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable stage III/IV or metastatic cutaneous or mucosal melanoma that has progressed on prior PD-1/PD-L1 therapy (including after PD-1+LAG-3) receive triplet immune checkpoint blockade: fianlimab (anti–LAG-3), cemiplimab (anti–PD-1), and ipilimumab (anti–CTLA-4). Excludes uveal melanoma and untreated/leptomeningeal CNS disease; definitively treated brain metastases allowed.

ClinicalTrials.gov ID: NCT06594991

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable metastatic uveal melanoma, ECOG 0–1, ICI-naïve, and with at least one measurable/injectable lesion are randomized to intratumoral RP2 plus nivolumab versus standard ipilimumab plus nivolumab. RP2 is a replication-competent HSV‑1 oncolytic immunotherapy engineered to express GALV-GP-R−, GM-CSF, and a local anti–CTLA-4–like molecule to promote oncolysis and immune activation alongside PD-1 blockade.

ClinicalTrials.gov ID: NCT06581406

A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination with Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients with Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and with Presence of Injectable Metastases

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable stage III–IV melanoma that is primary/acquired PD‑1/L1–refractory and has at least one injectable cutaneous/subcutaneous/nodal lesion (including treated, stable brain mets allowed) are randomized to pembrolizumab plus intratumoral L19IL2, L19TNF, or their combination. L19IL2 (IL‑2 fused to L19 antibody) and L19TNF (TNF‑α fused to L19) target the ED‑B domain of fibronectin to concentrate cytokines in tumor vasculature/ECM, aiming to convert PD‑1–refractory disease to responsive.

ClinicalTrials.gov ID: NCT06284590

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Previously untreated adults with unresectable stage III/IV, HLA‑A*02:01–positive melanoma (ECOG 0–1, known BRAF status) are randomized to brenetafusp (IMC‑F106C), a PRAME‑directed soluble TCR/CD3 bispecific (ImmTAC) that redirects T‑cell cytotoxicity, plus nivolumab vs standard nivolumab or nivolumab/relatlimab. Excludes prior systemic therapy for advanced disease and active/untreated CNS mets; primary endpoint is PFS.

ClinicalTrials.gov ID: NCT06112314